{"filings":[{"id":695358,"accession_number":"0001193125-26-241846","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-05-27T20:01:51+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.","Investors include BVF Partners, RA Capital, OrbiMed, Atlas Venture; led by BVF.","Closing expected May 28, 2026; net proceeds to advance bempikibart clinical trials and for working capital.","Registration rights agreement filed to register resale of shares and warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94504,"accession_number":"0001193125-26-205006","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q1 2026 net loss of $7.6M; bempikibart trial on track for mid-2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $50.8M at Mar 31; plus $14.2M ATM proceeds post-Q and milestone payments fund into 1H 2028.","Net loss $7.6M ($0.54 EPS) vs $11.0M ($0.90) in Q1 2025.","Bempikibart Part B SIGNAL-AA 36-wk topline data readout on track for mid-2026; first OLE patient dosed.","Completed $10.5M registered direct offering in Feb 2026 (1.7M shares/pre-funded warrants at $3.90).","R&D expenses fell to $3.2M from $7.1M due to headcount reduction and ADX-097 sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94503,"accession_number":"0001193125-26-177178","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio launches $75M ATM equity offering after exhausting prior $14.2M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold all $14.2M from prior ATM program; offering terminated as of April 24, 2026.","New prospectus supplement filed for up to $75M in common stock via Cantor Fitzgerald.","Shares offered under effective shelf registration statement (Form S-3, filed April 2025).","Goodwin Procter LLP issued legal opinion on the additional shares (Exhibit 5.1).","No offer or sale in jurisdictions where unregistered or unlawful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106939,"accession_number":"0001193125-26-129431","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Q32 Bio enters ATM sales agreement for up to $14.2M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. for at-the-market sales.","May sell shares with aggregate offering price up to $14.2 million via prospectus supplement filed March 27, 2026.","Sales made on Nasdaq or other trading markets; Agent receives 3.0% cash commission on gross proceeds.","Company not obligated to sell any shares; can suspend or terminate offering on notice to Agent.","Uses existing shelf registration statement Form S-3 (File No. 333-286491) effective April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106938,"accession_number":"0001193125-26-099328","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.","Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.","Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.","Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.","Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106937,"accession_number":"0001193125-26-054711","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.","Offering price equals Feb 13 closing price; pre-funded warrants exercisable at $0.0001/share.","Net proceeds for working capital, including advancing bempikibart for alopecia areata into future trials.","Closing expected Feb 18, 2026; led by new institutional investor with participation from existing investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123267,"accession_number":"0001193125-25-326821","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Q32 Bio director Mark Iwicki withdraws resignation, remains Board Chair and committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Iwicki had previously notified intention to resign from Board effective Dec 31, 2025 to focus on CEO role at Inhibikase Therapeutics.","On Dec 17, 2025, Iwicki withdrew resignation with full Board support, effective immediately, citing reduced board commitments.","He will continue as Chair of the Board and Compensation Committee, and as a member of the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123266,"accession_number":"0001193125-25-303115","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).","Eligible for up to $92.5M in development/regulatory milestones and $487.5M commercial milestones.","Tiered royalties on future sales of ADX-097 from low single-digit to mid-teen percent.","Cash runway extended into H2 2027; topline SIGNAL-AA Part B data expected mid-2026.","Q32 retains tissue-targeted complement platform including ADX-096; evaluating strategic options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123265,"accession_number":"0001193125-25-278805","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.","Cash and equivalents $49.0M as of Sep 30, 2025, expected to fund operations into 2027.","Net loss $7.4M ($0.60 per share) vs $17.6M ($1.46 per share) in Q3 2024, driven by lower R&D spend.","R&D expenses decreased to $3.6M from $14.3M; G&A to $4.0M from $4.5M year-over-year.","Emerging signs of clinical activity observed; preliminary PK shows steady-state drug concentration achieved 9 weeks earlier with loading regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123264,"accession_number":"0001193125-25-244262","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.","Enrollment exceeded initial target of ~20 patients, total 33 patients enrolled due to patient demand.","Part B includes loading regimen (200mg weekly x4 then every other week) with 36-week dosing; topline data expected mid-2026.","Preliminary PK data shows steady state achieved earlier with loading regimen; signs of clinical activity observed among early patients.","Company plans to advance to pivotal trials pending Part B results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139939,"accession_number":"0000950170-25-103526","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.","Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.","SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.","Fast Track designation granted by FDA for bempikibart in alopecia areata.","Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157549,"accession_number":"0001193125-25-146179","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.","Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.","Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.","Topline results from Part B of SIGNAL-AA expected in first half of 2026.","Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157548,"accession_number":"0001193125-25-142039","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Q32 Bio stockholders approve officer exculpation charter amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment limiting officer liability (Delaware law) approved; effective June 16, 2025.","David Grayzel, Isaac Manke, and Diyong Xu elected Class I directors for three-year terms.","Ernst & Young ratified as independent auditor for FY 2025 with 99.9% votes for.","Say-on-pay advisory vote passed with 7.45M for; one-year frequency selected for future votes.","Adjournment proposal also approved (7.88M for) but not needed as Proposal 2 passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157547,"accession_number":"0001193125-25-125435","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.","Also failed market value ($35M) and net income ($0.5M) alternatives.","Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 days.","Bempikibart-related liability of $55M from Amgen re-acquisition contributes to deficit.","No immediate effect on listing; stock continues trading under QTTB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157546,"accession_number":"0000950170-25-066366","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q1 net loss $11.0M; cash $65.5M, runs into 2H'26; first patient dosed in Phase 2a Part B for AA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).","Cash and equivalents $65.5M as of March 31, 2025; expected to fund operations into 2H'26.","First patient dosed in SIGNAL-AA Phase 2a Part B; topline data expected 1H'26.","Fast Track designation granted to bempikibart for alopecia areata; durable responses seen in late-breaking AAD presentation.","First patient dosed in Part A open-label extension; median follow-up 41 weeks shows maintenance or further hair growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157545,"accession_number":"0001193125-25-096703","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Q32 Bio director Mark Iwicki to resign from board, effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Iwicki notified his resignation from the board on April 25, 2025, effective December 31, 2025.","He will remain Chair and Compensation Committee chair, and Audit Committee member until the effective date.","Resignation is to reduce board commitments; no disagreement with the company.","He will continue as CEO of Inhibikase Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175919,"accession_number":"0000950170-25-036819","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.","Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.","SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.","Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).","Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175918,"accession_number":"0001193125-25-050372","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.","Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.","Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.","OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.","All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175917,"accession_number":"0000950170-25-017075","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.","Expects $1.1M severance charges; cash runway extended to second half of 2026.","Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.","Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175916,"accession_number":"0001193125-25-004976","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Q32 Bio updates corporate presentation for investor meetings; no financial details given","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation updated as of January 13, 2025, available on company website.","Overview covers immune therapeutics pipeline but no new financial or strategic data disclosed.","No material changes to guidance, pipeline, or leadership reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192831,"accession_number":"0001193125-24-274856","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio reports mixed Phase 2a results: AA signal, AD miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.","SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).","Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.","Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.","Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192830,"accession_number":"0000950170-24-122770","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.","Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.","Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.","ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.","Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209248,"accession_number":"0000950170-24-093295","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.","Cash and investments $107.6M as of June 30; expected funding into mid-2026.","Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.","ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.","Bempikibart AA Phase 2 topline results also expected in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209247,"accession_number":"0000950170-24-082307","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.","Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.","Primary endpoint: mean % change from baseline in EASI score at week 14.","SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.","CEO cites patient demand as driver of enrollment surpassing initial target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227190,"accession_number":"0000950170-24-056256","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.","Completed enrollment in bempikibart Phase 2 alopecia areata trial; topline results expected Q4 2024.","ADX-097 renal basket Phase 2 trial to start H1 2024; initial data expected by year-end 2024.","Reverse merger with Homology Medicines closed in March 2024; concurrent $42M private placement.","Net income of $1.0M due to $15.9M gain on convertible note conversion; R&D expense $9.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}